peramivir
prv
rapivab
biocryst
pharmaceut
inc
durham
nc
usa
first
intraven
neuraminidas
na
inhibitor
obtain
unit
state
food
drug
administr
approv
possess
antivir
activ
influenza
b
virus
optim
pharmacodynam
target
na
inhibitor
yet
determin
anim
model
suggest
area
curv
auc
closest
associ
improv
mortal
singl
multicent
openlabel
uncontrol
studi
assess
efficaci
safeti
pharmacokinet
prv
pediatr
patient
pandem
influenza
epidem
author
conclud
standard
weightbas
dose
regimen
pediatr
patient
similar
efficaci
safeti
outcom
compar
adult
patient
howev
investig
appear
exclud
pediatr
patient
diseas
sever
necessit
admiss
intens
care
unit
drug
develop
program
commonli
evalu
drug
pharmacokinet
pharmacodynam
properti
healthi
adult
pediatr
subject
commonli
antiinfect
drug
wide
evalu
popul
intend
use
especi
true
set
critic
ill
even
though
critic
ill
known
risk
factor
alter
drug
pharmacokinet
pharmacodynam
adult
pediatr
patient
lack
inform
regard
pharmacokinet
pharmacodynam
prv
pediatr
intens
care
unit
picu
popul
degre
alter
comparison
healthi
volunt
therefor
purpos
investig
report
pharmacokinet
case
seri
prv
picu
patient
treat
influenza
b
viral
infect
st
christoph
hospit
children
philadelphia
pa
critic
ill
patient
prescrib
antiinfect
normal
receiv
therapeut
drug
manag
tdm
describ
previous
therefor
effort
attain
pharmacokinet
pharmacodynam
target
dose
regimen
adjust
base
concentr
electron
medic
record
review
conduct
patient
undergo
prv
tdm
clinic
manag
januari
march
patient
admit
picu
receiv
prv
empir
definit
therapi
expect
durat
hour
elig
inclus
patient
cystic
fibrosi
acut
chronic
renal
failur
estim
creatinin
clearanc
use
modifi
schwartz
equat
receiv
extracorpor
therapi
continu
renal
replac
therapi
extracorpor
membran
oxygen
exclud
analysi
studi
conduct
agreement
declar
helsinki
current
amend
guidelin
good
clinic
practic
approv
drexel
univers
colleg
medicin
institut
review
board
demograph
clinic
microbiologicalvir
data
collect
biofir
filmarray
multiplex
polymeras
chain
reaction
pcr
respiratori
panel
biom
erieux
clinic
diagnost
salt
lake
citi
ut
techniqu
util
influenza
b
detect
methodolog
previous
describ
briefli
usual
minimum
two
blood
sampl
collect
per
patient
facilit
determin
patientspecif
pharmacokinet
paramet
subsequ
dose
alter
penetr
ratio
also
consid
design
dose
regimen
site
includ
epitheli
line
fluid
exampl
avail
achiev
target
pharmacodynam
exposur
primarili
auc
lghrml
prv
also
attempt
maintain
trough
level
approxim
lg
ml
peramivir
sampl
collect
regular
red
top
tube
subsequ
centrifug
within
minut
collect
g
minut
separ
plasma
transfer
cryovial
store
sampl
transport
dri
ice
refer
laboratori
upon
receipt
sampl
thaw
analyz
peramivir
concentr
determin
valid
liquid
chromatographytandem
mass
spectrometri
lcmsm
us
food
drug
administr
guidelin
wwwfdagovdownloadsdrug
guidancecomplianceregulatoryinformationguida
atlant
diagnost
laboratori
bensalem
pa
lcmsm
method
accur
precis
linear
rang
ngml
correl
coeffici
r
interday
assay
variabl
across
control
sampl
addit
pharmacokinet
analysi
techniqu
previous
describ
use
noncompartment
pharmacokinet
approach
patient
concentr
determin
respect
pharmacokinet
paramet
calcul
prv
free
drug
concentr
protein
bind
estim
util
sinc
packag
insert
pi
state
protein
bind
estim
patient
medic
record
review
assess
advers
event
specif
relat
prv
administr
emphasi
advers
event
report
previou
investig
prv
pediatr
patient
incid
total
patient
two
femal
nine
male
includ
investig
account
prv
sampl
tdm
patient
met
inclus
criteria
patient
receiv
form
extracorpor
therapi
patient
exclud
base
creatinin
clearanc
estim
mlmin
median
two
sampl
tdm
collect
per
patient
rang
sampl
median
age
year
interquartil
rang
iqr
year
median
weight
kg
iqr
kg
patient
demograph
prv
dose
inform
present
tabl
individu
patient
pharmacokinet
paramet
estim
present
tabl
figur
display
individu
prv
concentr
versu
time
profil
initi
prv
dose
rang
mgkgdose
patient
initi
dose
interv
dose
infus
minut
ten
patient
demonstr
larger
volum
distribut
v
compar
data
pi
previou
pediatr
prv
trial
eleven
patient
demonstr
increas
clearanc
cl
shorter
halflif
estim
compar
pi
previou
pediatr
prv
trial
patient
adjust
made
dose
regimen
specif
adjust
frequent
dose
interv
result
auc
exposur
closer
auc
target
describ
pi
previou
pediatr
prv
trial
allow
prolong
period
concentr
lgml
ten
patient
adjust
regimen
one
patient
adjust
regimen
advers
event
associ
prv
treatment
patient
test
posit
viru
via
multiplex
revers
transcriptasepolymeras
chain
reaction
rtpcr
test
eight
patient
test
posit
strain
influenza
three
patient
test
posit
influenza
b
four
patient
test
posit
multipl
virus
patient
respiratori
failur
three
patient
requir
intub
median
length
stay
day
iqr
day
death
cohort
median
durat
prv
treatment
day
iqr
day
patient
chang
oral
oseltamivir
finish
total
treatment
cours
day
includ
prv
oseltamivir
current
prv
fda
approv
indic
treatment
acut
uncompl
influenza
patient
year
age
older
symptomat
day
current
fda
recommend
dose
prv
pediatr
patient
year
age
acut
uncompl
influenza
singl
mg
kg
dose
maximum
dose
mg
administ
via
intraven
infus
minut
addit
influenza
prv
part
emerg
use
author
unit
state
patient
pandem
viru
given
everi
hour
period
day
current
fdaapprov
pediatr
dose
regimen
recommend
base
pharmacokinet
data
approxim
total
drug
exposur
auc
similar
achiev
adult
associ
safeti
efficaci
tabl
display
pharmacokinet
paramet
estim
pediatr
patient
base
data
pi
singl
pediatr
studi
pharmacokinet
data
present
studi
tabl
suggest
pharmacokinet
prv
differ
consider
picu
patient
confirm
influenza
viral
infect
compar
pharmacokinet
estim
report
pi
trial
pharmacokinet
data
picu
patient
suggest
dose
modif
would
need
prv
better
achiev
drug
exposur
similar
describ
earlier
pi
pharmacodynam
paramet
suggest
affect
morbid
mortal
auc
sinc
auc
marker
total
drug
exposur
sever
option
clinician
increas
total
drug
exposur
two
primari
option
either
increas
dose
mgkg
total
mg
dose
adjust
dose
interv
allow
frequent
drug
administr
current
recommend
state
upon
dilut
prv
concentr
suitabl
administr
administ
immedi
store
hour
unus
dilut
solut
discard
hour
combin
pharmacokinet
data
limit
stabil
inform
util
frequent
dose
regimen
ie
everi
everi
hour
may
allow
reduc
prv
wast
depict
approach
dose
regimen
modif
patient
popul
pharmacokinet
alter
unexpect
similar
chang
previous
describ
picu
set
tdm
becom
common
practic
care
critic
ill
children
recognit
pharmacokinet
variat
similar
describ
like
becom
customari
societi
healthcar
epidemiolog
america
shea
infecti
diseas
societi
america
idsa
guidelin
prevent
antimicrobi
resist
hospit
suggest
appropri
antimicrobi
stewardship
includ
optim
drug
select
dose
durat
treatment
well
control
antibiot
use
prevent
slow
emerg
resist
among
microorgan
often
one
dose
fit
mindset
hinder
clinician
treatment
infecti
diseas
paradigm
need
end
relianc
approv
dose
rather
achiev
target
serum
concentr
exposur
associ
safeti
efficaci
drug
develop
regulatori
process
problemat
underdos
low
exposur
associ
antiinfect
resist
increas
morbid
mortal
wherea
activ
manag
antiinfect
concentr
exposur
associ
improv
outcom
concept
replac
approv
dose
approv
concentr
exposur
tailor
dose
regimen
individu
patient
consid
interand
intrapati
variabl
across
popul
profound
grow
bodi
literatur
demonstr
benefit
antiinfect
tdm
optim
antiinfect
pharmacokinet
pharmacodynam
dramat
chang
infect
treat
allow
custom
optim
antiinfect
dose
allow
longer
lifespan
current
approv
antimicrobi
agent
futur
antiinfect
pipelin
similar
pharmacokinet
report
describ
previous
sever
limit
regard
pharmacokinet
case
seri
first
singl
center
experi
util
prv
suspect
confirm
influenza
viral
infect
second
singl
pharmacodynam
target
util
still
debat
regard
optim
clinic
pharmacodynam
target
third
blood
concentr
serv
surrog
marker
necessarili
reflect
prv
concentr
actual
potenti
site
infect
howev
blood
sampl
readili
avail
analyz
like
correl
concentr
site
infect
fourth
drug
concentr
measur
perform
total
drug
unbound
drug
concentr
static
protein
bind
estim
fifth
util
opportunist
sampl
strategi
may
ideal
fulli
character
pharmacokinet
prv
individu
child
sixth
repeat
prv
level
obtain
demonstr
whether
dosag
adjust
result
expect
observ
concentr
base
dose
calcul
adjust
whether
concentr
might
potenti
supratherapeut
howev
individu
paramet
estim
capabl
provid
reason
pharmacokinet
profil
individu
patient
commonli
employ
clinic
practic
aminoglycosid
vancomycin
pharmacokinet
prv
demonstr
picu
cohort
differ
comparison
halflif
hr
similar
pi
vd
lkg
similar
pi
cl
mlminkg
similar
pi
peak
lgml
auc
lghrml
similar
pi
similar
pi
author
trial
provid
actual
valu
yet
explicitli
state
similar
pi
manuscript
auc
area
curv
cl
clearanc
pi
packag
insert
pk
pharmacokinet
v
volum
distribut
packag
insert
data
see
ref
pediatr
trial
see
ref
healthi
pediatr
adult
patient
alter
dose
regimen
may
need
picu
patient
achiev
pharmacodynam
exposur
addit
investig
picu
popul
need
confirm
find
